New York City, NY -- (SBWIRE) -- 01/15/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Lantronix Inc (NASDAQ:LTRX), China Pharma Holdings, Inc. (NYSEMKT:CPHI), Hemispherx BioPharma, Inc (NYSEMKT:HEB), DARA Biosciences Inc (NASDAQ:DARA)
Lantronix Inc (NASDAQ:LTRX) gained 29.21%, trading on 1.45 million shares, to end the trade at $2.30. The stock changed hands in a range of $1.76 to $2.50, bringing its market capitalization to about $33.53 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $1.31 and was moved to the maximum level of $2.50. Lantronix, Inc. designs, develops, markets and sells products that make it possible to access, manage, control and configure electronic products over the Internet or other networks. Its device management solutions address applications that manage equipment at data centers and remote branch offices to provide management for information technology (IT) systems. Its network connectivity solutions are sold into market segments, including healthcare, industrial, security, energy, information technology (IT), data centers, transportation, government and others.
Why Should Investors Buy LTRX After The Recent Gain? Just Go Here and Find Out
China Pharma Holdings, Inc. (NYSEMKT:CPHI) added 28.52%, to complete the trading session at $0.540, with a total volume of 4.45 million shares. The stock, on average, trades on a volume of 84,887 shares. It floated in a range of $0.45 to $0.80 during the last trading session, with a beta value of 1.64. Its market capitalization now moved to about $23.52 million. In the past 52 weeks, the share price has not declined below $0.19 and above $0.80. China Pharma Holdings, Inc. is engaged in the development, manufacture and marketing of pharmaceutical products for human uses in connection with a range of high-incidence and high-mortality diseases and medical conditions in the People's Republic of China (the PRC).
What was the Moving Force behind CPHI on Bullish Run? Read This Research Report
Hemispherx BioPharma, Inc (NYSEMKT:HEB) recorded a gain of 23.74% and was in a range of $0.36-$0.45 before closing at $0.430. The stock completed the day with a total volume of 17.21 million shares, versus an average volume of 2.41 million shares. The share price hit its 52-week low of $0.18 and $0.45 was the best price. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
For How Long HEB will fight for Profitability? Read This Trend Analysis report
DARA Biosciences Inc (NASDAQ:DARA) added 19.53% yesterday, bringing its market capitalization around $23.69 million. The share price, after opening at $0.67, made a high of $0.81 and hovered above $0.65 to end the day at $0.765. The total number of shares that changed hands during the session was 8.54 million shares, as compared to average trading volume of 1.23 million shares. DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen).
For How Long DARA Gloss will Attract Investors? Find out via this report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)